Listar por autor "Oliver-Martos, Begoña"
Mostrando ítems 1-20 de 30
-
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFN beta in Multiple Sclerosis Patients According to the Therapeutic Response to IFN beta
Hurtado-Guerrero, Isaac; Pinto-Medel, María-Jesús; Urbaneja, Patricia; Rodríguez-Bada, José Luis; León, Antonio; Guerrero, Miguel; Fernández-Fernández, Óscar; Leyva-Fernández, Laura
; Oliver-Martos, Begoña[et al.] (Public Library of Science, 2017)
Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable ... -
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation
Hurtado-Guerrero, Isaac; Hernáez, Bruno; Pinto-Medel, Maria Jesús; Calonge, Esther; Rodríguez-Bada, José Luis; Urbaneja, Patricia; Alonso, Ana; Mena-Vázquez, Natalia; Aliaga, Pablo; Issazadeh-Navikas, Shohreh; Pavía-Molina, José; Leyva-Fernández, Laura; Alcamí, José; Alcamí, Antonio; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (MDPI, 2020)
Soluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ß) ... -
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
Hurtado-Guerrero, Isaac; Pinto-Medel, Maria Jesus; Urbaneja, Patricia; Rodríguez-Bada, José Luis; Ortega-Pinazo, Jesús; Serrano-Castro, Pedro Jesús; Fernández-Fernández, Óscar; Leyva-Fernández, Laura; Oliver-Martos, Begoña[et al.] (Nature, 2017)
Interferon beta (IFNβ) therapy has immunogenic properties and induces the development of neutralizing antibodies (NAbs). From the extensive literature focused in the development of NAbs in multiple sclerosis (MS) patients, ... -
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker
Órpez-Zafra, Teresa; Pavía-Molina, José; Hurtado-Guerrero, Isaac; Pinto-Medel, Maria Jesús; Rodríguez-Bada, José Luis; Urbaneja, Patricia; Suardíaz García, Margarita; Villar, Luisa M; Comabella, Manuel; Montalban, Xavier; Alvarez-Cermeño, Jose C; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (SAGE Journals, 2017)
Background: The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in ... -
Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis
Órpez-Zafra, Teresa; Pavía-Molina, José; Pinto-Medel, Maria Jesús; Hurtado-Guerrero, Isaac; Rodríguez-Bada, José Luis; Martín-Montañez, Elisa; Fernández Fernández, Óscar; Leyva-Fernández, Laura; Oliver-Martos, Begoña[et al.] (Taylor & Francis, 2015)
Aim: The soluble isoform of the IFN-β receptor (sIFNAR2) can bind IFN-β and modulate its activity, although its role in autoimmune diseases remains unknown. Methods: A recombinant human sIFNAR2 protein was cloned, ... -
Early development of anti-natalizumab antibodies in MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Urbaneja, Patricia; Maldonado-Sanchez, Rafael; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (SpringerLink, 2013)
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Pinto-Medel, Maria Jesús; Mayorga Mayorga, Cristobalina; García-León, Juan Antonio; Maldonado-Sanchez, Rafael; Suardíaz García, Margarita; Guerrero, Miguel; Luque, Gloria; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (Elsevier, 2011)
IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged ... -
Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis
Marín Bañasco, Carmen; Benabdellah, K; Melero-Jerez, C; Oliver-Martos, Begoña; Pinto-Medel, Maria Jesús; Hurtado-Guerrero, Isaac; de Castro, Fernando; Clemente, Diego; Fernández-Fernández, Óscar; Martín, F; Leyva-Fernández, Laura; Suardíaz García, Margarita[et al.] (British Pharmacological Society, 2017)
Background and purpose: Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising ... -
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)
Fernández Fernández, Óscar; Rodríguez-Antigüedad, Alfredo; Pinto-Medel, María Jesús; Mendibe, Mari Mar; Acosta, Nestor; Oliver-Martos, Begoña; Guerrero, Miguel; Papais-Alvarenga, Marcos; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (Springer, 2009)
Genetic susceptibility to multiple sclerosis (MS) is associated with genes of the major histocompatibility complex, particularly with the HLA DRB1*1501-DQA1*0102-DQB1*0602 haplotype in Caucasians. To investigate the ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
Leyva-Fernández, Laura; Fernández Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández Sánchez, Victoria Eugenia; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María-Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNbeta treatment response in a group of 147 patients ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández, Victoria E.; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005-04-22)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNβ treatment response in a group of 147 patients and ... -
Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Mena-Vázquez, Natalia; Godoy-Navarrete, Francisco Javier; Lisbona-Montañez, José Manuel; Redondo-Rodríguez, Rocío; Manrique-Arija, Sara; Rioja, Jose; Mucientes, Arkaitz; Ruiz-Limón, Patricia; García-Studer, Aimara; Ortiz-Marquez, Fernando; Oliver-Martos, Begoña; Cano-García, Laura; Fernández-Nebro, Antonio[et al.] (MDPI, 2023-04-05)
This study aimed to identify inflammatory factors and soluble cytokines that act as biomarkers in the diagnosis and prognosis of rheumatoid arthritis-associated interstitial lung disease (RAILD). We performed a nested ... -
Interferon receptor expression in multiple sclerosis patients
Oliver-Martos, Begoña; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; León, Antonio; Luque, Gloria; C Lopez, Juan; Tamayo, Jose A; Pinto-Medel, Maria Jesús; De Ramón, Enrique; Blanco, Eva; Alonso, Ana; Fernández Fernández, Óscar[et al.] (Elsevier, 2006)
To determine the gene expression of IFNAR1, IFNAR2 and MxA protein and the association with IFNbeta treatment response in MS patients. MS patients treated with IFNbeta had a significant decrease in IFNAR1 and IFNAR2 ... -
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients
García-León, Juan Antonio; Pinto-Medel, Mª Jesús; García-Trujillo, Lucía; López-Gómez, Carlos; Oliver-Martos, Begoña; Prat-Arrojo, Isidro; Marín-Bañasco, Carmen; Suardíaz-García, Margarita; Maldonado-Sánchez, Rafael; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2011)
Killer cell immunoglobulin-like receptors (KIRs) are regulators of cytolytic activity of natural killer and certain T cells through interactions with human leukocyte antigen (HLA) class I ligands. KIRs have been shown to ... -
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients.
García-León, Juan Antonio; Pinto-Medel, María-Jesús; García-Trujillo, Lucía; López-Gómez, Carlos; Oliver-Martos, Begoña; Prat-Arrojo, Isidro; Marín-Bañasco, Carmen; Suardíaz-García, Margarita; Maldonado-Sánchez, Rafael; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2011-09)
Killer cell immunoglobulin-like receptors (KIRs) are regulators of cytolytic activity of natural killer and certain T cells through interactions with human leukocyte antigen (HLA) class I ligands. KIRs have been shown to ... -
Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response
García-León, Juan Antonio; López-Gómez, Carlos; Orpez-Zafra, Teresa; Reyes-Garrido, Virginia; Marín Bañasco, Carmen; Oliver-Martos, Begoña; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Springer Link, 2014)
Background: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection
Oliver-Martos, Begoña; Orpez, Teresa; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; López-Gómez, Carlos; Marín, Carmen; Luque, Gloria; Fernández Fernández, Óscar[et al.] (Elsevier, 2009)
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients
Malhotra, Sunny; Costa, Carme; Eixarch, Herena; Keller, Christian W; Lukas Amman, Lukas; Martínez-Banaclocha, Helios; Midaglia, Luciana; Sarró, Eduard; Isabel Machín-Díaz, Isabel; M Villar, Luisa; Triviño, Juan Carlos; Oliver-Martos, Begoña; Navarro Parladé, Laura; Calvo-Barreiro, Laura; Matesanz, Fuencisla; Vandenbroeck, Koen; Urcelay, Elena; María-Luisa Martínez-Ginés, María-Luisa; Tejeda-Velarde, Amalia; Fissolo, Nicolás; Castilló, Joaquín; Sanchez, Alex; Robertson, Avril A B; Clemente, Diego; Prinz, Marco; Pelegrin, Pablo; Lünemann, Jan D; Espejo, Carmen; Montalban, Xavier; Comabella, Manuel[et al.] (Oxford Academic, 2020)
Primary progressive multiple sclerosis is a poorly understood disease entity with no specific prognostic biomarkers and scarce therapeutic options. We aimed to identify disease activity biomarkers in multiple sclerosis by ...